Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies - Wikidata - awgldk - TriplyDB

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

http://www.wikidata.org/entity/Q35652113

about

VEGF inhibition and renal thrombotic microangiopathy Anti-angiogenic alternatives to VEGF blockade Mouse models for studying angiogenesis and lymphangiogenesis in cancer r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway.The VEGF family in cancer and antibody-based strategies for their inhibition.In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies.Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60.Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies.Angiogenic factors and preeclampsia.Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice.Functional analysis and transcriptional output of the Göttingen minipig genome.Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class.VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations 68Ga-TRAP-(RGD)3 Hybrid Imaging for the In Vivo Monitoring of αvß3-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer.VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade.Genetically engineered mouse models in cancer research VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response.Abnormal angiogenesis in diabetic nephropathy.Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor.Transplantation of PEDF-transfected pigment epithelial cells inhibits corneal neovascularization in a rabbit model.Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.Did animal offer relevant model for Bevacizumab testing?Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target.Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice.Vascular endothelial growth factor-B: Impact on physiology and pathology.Engineering therapeutic monoclonal antibodies.Safety Pharmacology Society: 9th Annual Meeting.A protein kinase Cepsilon-anti-apoptotic kinase signaling complex protects human vascular endothelial cells against apoptosis through induction of Bcl-2.Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.Bevacizumab Diminishes Inflammation in an Acute Endotoxin-Induced Uveitis Model.

P2860

Q24632792-4F9C5FD8-F418-4BEA-B28E-EDF028DD8BE7 Q26775947-B33B8EC5-EBB6-461E-B7EE-A1F53B73AD6E Q27003898-F107CBC6-6C96-4A1A-8D4C-A210350BC90B Q27321768-C8A5DB6C-8B00-4DEB-A518-382144895377 Q28537681-8EC4DACF-3084-4667-AF0F-D7A399E650AF Q33413979-05EB3D56-8670-45A0-8B54-7869D5FEAFDA Q33535171-1EDB51BC-628F-4E4E-8DE8-F5C692AF9487 Q33733437-A355BE01-51B5-43FA-8246-6392B2CE3704 Q33819576-52E545DA-8BFF-4EB0-BCB2-D531B8BC2099 Q33858304-A4A16CE7-D0C6-45A3-9988-FF22C796CBF6 Q34079689-F2255EE6-8830-4905-B062-8FC4B40024F6 Q34714082-DF7002A7-C79F-4469-8487-F742F02838BD Q35836870-DF11C127-5D85-4233-90B4-B7DA49813651 Q35843080-32DDA0E2-953A-4F52-8B2A-495AB3A20478 Q35864213-2BDB0518-AFBB-4753-9927-CBF7BC0D300E Q36216197-7A59B159-D3F6-4557-90AD-D976F22DD42A Q36228314-E7A7149D-5D70-40F2-BFAB-832FDAA6FA25 Q36276765-3AE10512-CB5F-475B-B89B-D26A4750A286 Q36497718-4E5C0367-B5C5-4A20-86C3-D0DC59FDC2D2 Q36502881-6336779B-98CB-45E6-AC6C-463BD4C648D7 Q37184559-F2041D66-74C4-4952-81A4-533C45E262A6 Q37236268-850B776D-5924-4257-8396-5AF98EF92500 Q37524215-4E2FD35A-2911-47AF-94D4-D75DB58C472B Q38025261-61C30D32-370D-4F1B-B3B2-D3D4E9487A03 Q38441344-72BFF34C-DFDD-43B4-ABF6-2141B47C22A9 Q38908590-C74792BF-E3D3-456C-8769-52147403F76B Q39345414-04F91508-8700-45FF-9798-159FCB5E5D2F Q39473604-1590354A-69C6-4378-A659-19B5C36B7A76 Q39474834-59E263D8-D8B0-45AE-A3E7-85F187854450 Q42144314-343A6111-7C6F-4337-B08C-D067F5895DC6 Q43245707-625D8AFF-722F-4968-BD47-9F6300861CE2 Q43420262-D8F9C74E-5EB3-4485-BC2E-85D57E6AB2DF Q45159120-9F403D48-492A-4003-ABFD-9FC3B95073F0 Q47450318-10E98F63-B83D-452C-B815-BABEFF034E15 Q47820029-DA5A80D9-B1C7-4DD7-BDA2-262A9D8A283C Q48309631-11AEA3E1-B09C-496A-A058-74FBF3EAB3C3 Q53530451-55530868-5D42-404F-B123-FFAC95D008E2 Q54979386-1D45AB04-400F-43DE-8EA1-3F7E446C7F3D Q55412994-E806FCD2-107B-48F0-9D83-61A6506D5360

P2860

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

http://www.wikidata.org/entity/Q35652113

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Mice expressing a humanized fo ...... ficacy of anti-VEGF antibodies

@ast

Mice expressing a humanized fo ...... ficacy of anti-VEGF antibodies

@en

type

label

Mice expressing a humanized fo ...... ficacy of anti-VEGF antibodies

@ast

Mice expressing a humanized fo ...... ficacy of anti-VEGF antibodies

@en

prefLabel

Mice expressing a humanized fo ...... ficacy of anti-VEGF antibodies

@ast

Mice expressing a humanized fo ...... ficacy of anti-VEGF antibodies

@en

P1433

Q35652113-5B44A47E-89B8-4B0B-BC40-BE14BA75FC3B

P1476

Q35652113-979F071F-E3D8-404E-93EC-E6CB799A5B95

P2093

Q35652113-0E3505A6-E492-46AD-8058-335182142902

Q35652113-12B173EF-6384-49A5-95DD-36274C739576

Q35652113-22B207B0-ED9F-4AD3-A921-DB524045EAB9

Q35652113-2C91FFA7-D226-401E-AE30-7CEFE3854977

Q35652113-3BF46908-B206-401D-AC83-1024A984BE7B

Q35652113-3D3515F1-F923-4897-86B5-C298911D2F8A

Q35652113-43E33536-CE2E-411D-A216-25790CDF3679

Q35652113-44D5FF9E-3AC4-446B-B570-579197CE4A83

Q35652113-4A254CCB-9A2F-4AA3-9663-235075A7E6A6

Q35652113-5A34DA0F-1BB0-42AB-8DB8-DC963145F4B9

P2860

Q35652113-023D2E1F-083E-4066-8C17-4775A22D8690

Q35652113-109B2C43-E005-4586-94D8-FC408B06AFD8

Q35652113-14E4BE69-4064-4157-A70A-C6B22D5FB5B7

Q35652113-1BDBD85A-7303-4887-ADC7-D379D89EBE5D

Q35652113-1E80C7C2-E098-4B4F-81A6-99FDCEFD9BDE

Q35652113-24743DB8-3F8C-48FE-8A2C-9A62111EA6A6

Q35652113-26610FC6-DAE2-4B0C-94EE-CBDF3A17CD74

Q35652113-2B69F68C-2623-4723-9B53-F377C0D54B3A

Q35652113-2DC15BF2-617F-480D-AD99-D916E2F5A825

Q35652113-3362355C-24CF-4820-AA01-F9B0A1598A87

P304

Q35652113-59D39A4C-791B-4E1B-A3DA-FD9812B63687

P31

Q35652113-B4453FCD-CB6F-40C0-AEF0-6692EB803B8D

P356

Q35652113-851676F5-7D14-4642-A306-5E151EA2048B

P407

Q35652113-443AD240-D39C-4220-AD2B-5E222EA16CA9

P433

Q35652113-1B208EC6-5037-4008-8C7D-4712ECCFE034

P478

Q35652113-54C2F6D7-009E-42A6-957B-0CE7AD1EEC83

P50

Q35652113-514EDBE3-2C4C-4B7D-9B0E-F3628669504E

P577

Q35652113-BCDDE111-F64B-4E86-A055-51B881CAB5F2

P5875

Q35652113-7CA8DC90-67C9-460E-8862-C8ECE47C6BBF

P698

Q35652113-3F433475-C4F7-4194-A463-903FBC6AC4F8

P932

Q35652113-34F6705B-4C68-4819-90CF-ABFE177DE36D

P356

PNAS.0611492104

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Mice expressing a humanized fo ...... ficacy of anti-VEGF antibodies

@en

P2093

Bing Li

http://www.w3.org/2001/XMLSchema#string

Chingwei V Lee

http://www.w3.org/2001/XMLSchema#string

Christine Olsson

http://www.w3.org/2001/XMLSchema#string

David Xie

http://www.w3.org/2001/XMLSchema#string

Franklin Peale

http://www.w3.org/2001/XMLSchema#string

Germaine Fuh

http://www.w3.org/2001/XMLSchema#string

Hans-Peter Gerber

http://www.w3.org/2001/XMLSchema#string

Henry Lowman

http://www.w3.org/2001/XMLSchema#string

Johnny Gutierrez

http://www.w3.org/2001/XMLSchema#string

Lanlan Yu

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

P304

3478-3483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0611492104

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

Christian Wiesmann

P577

2007-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6445908

http://www.w3.org/2001/XMLSchema#string

P698

17360669

http://www.w3.org/2001/XMLSchema#string

P932

1805509

http://www.w3.org/2001/XMLSchema#string